Subcutaneous Implantable Cardioverter-defibrillator in Preventing Ventricular Arrhythmia and Sudden Cardiac Death – A Single-center Experience

Abstract

Subcutaneous implantable cardioverter-defibrillator (S-ICD) differs from the transvenous ICD (TV-ICD) system in its extrathoracic and extravascular localization, eliminating the risks arising from vascular access and leading to fewer complications. The objective was to describe the functionality and postoperative complications associated with SICD implants in patients with cardiac dysfunctions. We enrolled six patients eligible for SICD due to either anterior wall myocardial infarction or left ventricular dysfunction, who reported to our tertiary cardiac care center from June 2020 to March 2022. Preprocedural evaluation for various cardiac parameters was carried out. The procedure was performed under antibiotic prophylaxis. Two incision techniques were used for the SICD placement. The primary and secondary endpoints for the cases were set to evaluate device-related complications and predictive outcomes, respectively. Subcutaneous implantable defibrillator was placed in six male patients aged 36−51 years. The procedure demonstrated an efficient, reliable, and well-accepted modality in eliminating ventricular tachycardia, ventricular fibrillation, and sudden cardiac death. In addition, postoperative complications, such as device infection, pocket hematoma, blood transfusion, prolonged hospitalization, cardiac perforation or tamponade, lead repositioning, or inappropriate shocks, were not reported in the 2 years of follow-up. Subcutaneous implantable defibrillator promises to offer a suitable and safer option for TV-ICD, especially in young patients. It circumvents the need to enter the vasculature or cardiac chambers. As a result, fewer reported lead-related complications, better cosmetic appearance, and greater immediate postoperative comfort as it permits free shoulder movement.